Maxor National Pharmacy Services, LLC (“Maxor”), today announced that Vertex Pharmaceuticals Inc. has now included Maxor Specialty, comprised of IV Solutions and Pharmaceutical Specialties (“PSI”), in its specialty pharmacy network. Effectively immediately, patients may now utilize Maxor Specialty for Orkambi® and Kalydeco®, two leading medications used in the treatment of certain types of Cystic Fibrosis (“CF”).
Cystic Fibrosis (CF) is a genetic condition that affects the body's lungs, sweat glands, and digestive system.
The CF community is a support group that provides tools and education to CF patients and their families. Maxor Specialty is a part of this community. We manage and care for the complete needs of our CF patients.
Rare Disease Day, launched in Europe in 2008, is held the last day of February every year and seeks to raise awareness of the impact that rare or orphan diseases have on the lives of patients and those who care for them. The USA joined the campaign in 2009 and over 80 countries throughout the world participated in 2016. The theme for 2017 is “RESEARCH” and the slogan is “With research, possibilities are limitless.”
Science continually opens windows and doors, offering insight into diseases and conditions and how to cure or at least manage them. Pharmaceutical companies invest heavily in research, particularly for common diseases. Rare diseases are often neglected, to the point where they are also known as “orphan diseases.”
Seeking relief from the rising costs of your pharmacy benefits? If you’re attending the 61st Annual Employee Benefits Conference in Honolulu, Hawaii, November 8-11, 2015, be sure to stop by Booth #832 to learn about the MaxorPlus way of managing pharmacy benefits and what we can do for you.
Prescription drug costs are scary. With the industry trends and issues with generic prices, clients continue seeing their drug spend increase each year. How do you combat this? Read more to see the MaxorPlus solution, as written by Jen Kirsch, Regional Sales Director, MaxorPlus.
Yes, yes they are. Compounds, specialty drugs, and price increases … oh my!
Prescription drugs have been in the news non-stop for the past several weeks. Headlines include: